Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: FKBP3 (ImmuneEditome ID:2287)

1. Gene summary of enriched editing regions for FKBP3

Gene summary

Gene information	Gene symbol	FKBP3
	Gene ID	2287
	GeneSynonyms	FKBP-25\|FKBP-3\|FKBP25\|PPIase
	GeneCytomap	14q21.2
	GeneType	protein-coding
	GeneDescription	peptidyl-prolyl cis-trans isomerase FKBP3\|25 kDa FK506-binding protein\|25 kDa FKBP\|FK506 binding protein 3, 25kDa\|FK506-binding protein 25, T-cell\|FK506-binding protein 3\|PPIase FKBP3\|immunophilin FKBP25\|rapamycin binding protein\|rapamycin-selective 25 kDa immunophilin\|rotamase
	GeneModificationdate	20230517
	UniprotID	Q00688;G3V5F2
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr14:45116641-45117197:-	ENST00000216330.6	ENSG00000100442.9	FKBP3	intronic	AluSx	chr14:45116641-45117197:-.alignment
chr14:45116641-45117197:-	ENST00000396062.3	ENSG00000100442.9	FKBP3	intronic	AluSx	chr14:45116641-45117197:-.alignment
chr14:45131337-45133351:-	ENST00000557324.4	ENSG00000100442.9	FKBP3	exonic	AluSx,AluSc8,MIR	chr14:45131337-45133351:-.alignment

Top

2. Tumor-specific enriched editing regions for FKBP3

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

Type

Boxplot

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr14:45131337-45133351:-	LUSC	Path	EER	1.8191e-02	3.8225e-02	-0.2538
ENSG00000100442.9,FKBP3	LUSC	Path	EAG	1.7317e-02	3.6429e-02	-0.2542

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for FKBP3

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

4. Enriched editing regions and immune related splicing for FKBP3

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

More results

Top

5. Enriched editing regions and immune infiltration for FKBP3

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr14:45131337-45133351:-	BLCA	EER	Dendritic_cells_resting	8.4969e-03	0.3038
ENSG00000100442.9,FKBP3	BLCA	EAG	Dendritic_cells_resting	6.8245e-03	0.3099
chr14:45131337-45133351:-	BRCA	EER	T_cells_CD4_memory_resting	3.1947e-02	-0.1331
ENSG00000100442.9,FKBP3	BRCA	EAG	T_cells_CD4_memory_resting	3.8844e-02	-0.1280
chr14:45131337-45133351:-	ESCA	EER	Mast_cells_activated	3.4549e-02	-0.2206
ENSG00000100442.9,FKBP3	ESCA	EAG	T_cells_follicular_helper	4.1906e-02	0.2114
ENSG00000100442.9,FKBP3	HNSC	EAG	Neutrophils	2.9365e-02	-0.4196
chr14:45131337-45133351:-	KIRC	EER	Dendritic_cells_activated	2.7099e-02	0.2700
ENSG00000100442.9,FKBP3	KIRC	EAG	Dendritic_cells_activated	2.6169e-02	0.2716
chr14:45131337-45133351:-	KIRP	EER	Eosinophils	1.1154e-02	0.2756
ENSG00000100442.9,FKBP3	KIRP	EAG	Eosinophils	1.1153e-02	0.2756
chr14:45131337-45133351:-	LGG	EER	Macrophages_M0	1.0241e-02	0.1546
ENSG00000100442.9,FKBP3	LGG	EAG	Macrophages_M0	9.8667e-03	0.1554
chr14:45131337-45133351:-	LUSC	EER	Neutrophils	3.4106e-03	0.3528
ENSG00000100442.9,FKBP3	LUSC	EAG	Neutrophils	3.2295e-03	0.3522
chr14:45131337-45133351:-	OV	EER	Mast_cells_activated	2.1622e-02	-0.2169
ENSG00000100442.9,FKBP3	OV	EAG	Mast_cells_activated	7.6698e-03	-0.2453
chr14:45131337-45133351:-	PRAD	EER	T_cells_CD4_memory_activated	1.9914e-02	0.2882
ENSG00000100442.9,FKBP3	PRAD	EAG	Neutrophils	4.4332e-02	0.2447
chr14:45131337-45133351:-	SKCM	EER	Mast_cells_resting	3.6951e-02	-0.2678
ENSG00000100442.9,FKBP3	SKCM	EAG	T_cells_follicular_helper	2.8395e-02	0.2763
ENSG00000100442.9,FKBP3	TGCT	EAG	Neutrophils	2.9161e-02	-0.3690
chr14:45131337-45133351:-	THCA	EER	T_cells_regulatory_(Tregs)	4.7011e-02	0.2200
ENSG00000100442.9,FKBP3	THCA	EAG	T_cells_regulatory_(Tregs)	4.7512e-02	0.2195

Top

6. Enriched editing regions and immune gene sets for FKBP3

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events

cancer

Type

Buffa_P

Buffa_R

Ragnum_P

Ragnum_R

Winter_P

Winter_R

HALLMARK_P

HALLMARK_R

CorrelationPlot

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr14:45131337-45133351:-	BLCA	GSVA_HALLMARK_MYOGENESIS	EER	1.7507e-03	0.3578
ENSG00000100442.9,FKBP3	BLCA	GSVA_HALLMARK_MYOGENESIS	EAG	7.5347e-03	0.3063
ENSG00000100442.9,FKBP3	BRCA	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EAG	1.6317e-02	0.1485
chr14:45131337-45133351:-	BRCA	GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING	EER	1.8036e-02	0.1466
chr14:45131337-45133351:-	CESC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.3671e-02	0.3092
ENSG00000100442.9,FKBP3	CESC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	4.6456e-03	0.3495
ENSG00000100442.9,FKBP3	ESCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EAG	3.1755e-02	0.2229
chr14:45131337-45133351:-	ESCA	GSVA_HALLMARK_ALLOGRAFT_REJECTION	EER	4.8180e-02	0.2066
ENSG00000100442.9,FKBP3	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EAG	7.7223e-03	-0.3228
chr14:45131337-45133351:-	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	8.2329e-03	-0.3203
chr14:45131337-45133351:-	KIRP	GSVA_HALLMARK_NOTCH_SIGNALING	EER	2.8805e-02	-0.2387
ENSG00000100442.9,FKBP3	KIRP	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	2.7764e-02	-0.2402
ENSG00000100442.9,FKBP3	LGG	GSVA_HALLMARK_HYPOXIA	EAG	1.4108e-02	0.1479
chr14:45131337-45133351:-	LGG	GSVA_HALLMARK_HYPOXIA	EER	1.4553e-02	0.1472
chr14:45131337-45133351:-	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.8283e-03	-0.3593
ENSG00000100442.9,FKBP3	LUSC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.0412e-03	-0.3542
chr14:45131337-45133351:-	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	6.8046e-03	0.2544
ENSG00000100442.9,FKBP3	OV	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	9.0456e-03	0.2404
ENSG00000100442.9,FKBP3	SKCM	GSVA_HALLMARK_P53_PATHWAY	EAG	4.2797e-02	-0.2561
chr14:45131337-45133351:-	SKCM	GSVA_HALLMARK_P53_PATHWAY	EER	4.0398e-02	-0.2632
chr14:45131337-45133351:-	STAD	GSVA_HALLMARK_APICAL_SURFACE	EER	3.9576e-03	0.2915
ENSG00000100442.9,FKBP3	STAD	GSVA_HALLMARK_APICAL_SURFACE	EAG	5.6592e-04	0.3294
ENSG00000100442.9,FKBP3	TGCT	GSVA_HALLMARK_MYC_TARGETS_V1	EAG	2.2001e-02	-0.3860
ENSG00000100442.9,FKBP3	THYM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	4.5159e-02	-0.2936

Top

7. Enriched editing regions and drugs for FKBP3

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr14:45131337-45133351:-	BLCA	Dasatinib	EER	8.2551e-03	-0.3049
ENSG00000100442.9,FKBP3	BLCA	Dasatinib	EAG	1.4338e-02	-0.2817
ENSG00000100442.9,FKBP3	BRCA	Axitinib	EAG	1.4556e-02	0.1511
chr14:45131337-45133351:-	BRCA	Axitinib	EER	1.6328e-02	0.1488
chr14:45131337-45133351:-	CESC	BMS.536924	EER	1.3891e-02	0.3085
ENSG00000100442.9,FKBP3	CESC	BMS.536924	EAG	1.0737e-02	0.3169
ENSG00000100442.9,FKBP3	ESCA	BMS.509744	EAG	2.1647e-02	-0.2379
chr14:45131337-45133351:-	ESCA	BMS.509744	EER	2.6418e-02	-0.2315
chr14:45131337-45133351:-	GBM	DMOG	EER	4.3828e-02	-0.2754
ENSG00000100442.9,FKBP3	GBM	DMOG	EAG	4.9168e-02	-0.2665
ENSG00000100442.9,FKBP3	HNSC	JNK.9L	EAG	3.7605e-02	0.4021
ENSG00000100442.9,FKBP3	KIRC	Bexarotene	EAG	2.2822e-03	0.3666
chr14:45131337-45133351:-	KIRC	Bexarotene	EER	3.0507e-03	0.3567
ENSG00000100442.9,FKBP3	LGG	CCT007093	EAG	6.5473e-03	0.1636
chr14:45131337-45133351:-	LGG	CCT007093	EER	6.8380e-03	0.1628
ENSG00000100442.9,FKBP3	LUAD	CMK	EAG	3.5346e-02	0.2234
chr14:45131337-45133351:-	LUAD	CMK	EER	4.5513e-02	0.2150
chr14:45131337-45133351:-	LUSC	Gefitinib	EER	6.4799e-04	-0.4062
ENSG00000100442.9,FKBP3	LUSC	Lapatinib	EAG	8.5081e-04	-0.3952
ENSG00000100442.9,FKBP3	OV	AZD.0530	EAG	2.4223e-02	0.2083
ENSG00000100442.9,FKBP3	PRAD	AMG.706	EAG	3.1369e-02	0.2613
chr14:45131337-45133351:-	PRAD	Embelin	EER	2.6955e-02	0.2744
chr14:45131337-45133351:-	STAD	Doxorubicin	EER	8.7773e-03	-0.2661
ENSG00000100442.9,FKBP3	STAD	CI.1040	EAG	4.6570e-02	0.1938
ENSG00000100442.9,FKBP3	TGCT	BIRB.0796	EAG	3.9595e-02	-0.3495
chr14:45131337-45133351:-	THYM	Dasatinib	EER	3.6397e-02	0.3128
ENSG00000100442.9,FKBP3	THYM	Elesclomol	EAG	1.1426e-02	0.3659
ENSG00000100442.9,FKBP3	UCEC	BMS.708163	EAG	4.3497e-02	-0.3990

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType